EP Patent

EP3134398A1 — Autotaxin inhibitors

Assigned to Novartis AG · Expires 2017-03-01 · 9y expired

What this patent protects

The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in the treatment of an ATX-dependent or ATX-mediated disease or condition.

USPTO Abstract

The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in the treatment of an ATX-dependent or ATX-mediated disease or condition.

Drugs covered by this patent

Patent Metadata

Patent number
EP3134398A1
Jurisdiction
EP
Classification
—
Expires
2017-03-01
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.